Lexicon Pharmaceuticals LXRX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's EPS (diluted)?
- Lexicon Pharmaceuticals (LXRX) reported EPS (diluted) of $0.00 in Q1 2026.
- How has Lexicon Pharmaceuticals's EPS (diluted) changed year-over-year?
- Lexicon Pharmaceuticals's EPS (diluted) increased by 100.0% year-over-year, from -$0.07 to $0.00.
- What is the long-term trend for Lexicon Pharmaceuticals's EPS (diluted)?
- Over 2 years (2023 to 2025), Lexicon Pharmaceuticals's EPS (diluted) has grown at a -58.2% compound annual growth rate (CAGR), from -$0.80 to -$0.14.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.